Mycophenolate mofetil for

Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgam BR. (2007) Mycophenolate mofetil for induction therapy of lupus nephritis A systematic review and meta-analysis. Clin J Am Soc Nephrol 2 968-975. 

A 59-year-old woman taking pravastatin 20 mg/day tolerated immunosuppression with ciclosporin, prednisone, and mycophenolate mofetil for 4 years after heart transplantation. After switching from pravastatin to simvastatin she developed severe muscle weakness and laboratory evidence of muscle breakdown. The biochemical markers of rhabdomyolysis did not normalize until after repeat hemodialysis. Clinical improvement did not occur until after 5 months. 

Richardson, PJ)., James, P.D., Ryder, S.D. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant. J. Hepatol. 2000 33 371 -375... 

Preddie DC MG, Radhakrishnan J, NickolasTL, D AgatiVD, Schwimmer JA, Gardenswartz M, Rosen R, Appel GB. Mycophenolate Mofetil for the Treatment of Interstitial Nephritis. Clin J Am Soc Nephro 2006,-11 718-22. 

Pescovitz MD, Govani M. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients. Am J Kidney Dis 2001 38 S16-S21. 

Al-Aly Z, Sachdeva A, Philoctete Ashley JM, Bastani B. Preliminary experience with mycophenolate mofetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicity. Nephrology (Carlton) 2006 11 151-155. 

The Mycophenolate Mofetil Acute Renal Rejection Study Group. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection three-year follow-up. Transplantation 2001 71 1091-1097. 

Cox VC, Ensom MHH. Mycophenolate mofetil for solid organ transplantation Does the evidence support the need for clinical pharmacokinetic monitoring Ther Drug Monit 2003 25 137-157. 

Kirby B, Yates VM. Mycophenolate mofetil for psoriasis. Br J Dermatol 1998 139 357. 

Meiser, B. M., Pfeiffer, M., Schmidt, D., Ueherfuhr, P., Reichenspumer, H., Paulus, D., Scheidt, W. V., Kreuzer, E., Seidel, D., and Reichart, B. (1999). The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels. Transpl. Proc. 31, 84-87. 

Sollinger HW. Mycophenolate mofetil for tiie prevention of acute rejection in primary care cadaveric renal allograft recipients. Transplantation (1995) 60, 225-32. 

Hematologic Agranulocytosis occurred in a 27-year-old female renal transplant recipient who took mycophenolate mofetil for 2 weeks, despite dosage reduction and the use of granulocyte colony-stimulating factor (G-CSF) [86" ]. After a switch from mycophenolate mofetil to azathioprine, the neutrophil count normalized. 

Tumorigenidty A woman with systemic lupus erythematosus who had taken mycophenolate mofetil for 8 years developed a primary lymphoma of the central nervous system with histology compatible with Epstein-Barr virus-driven B ceU lympho-proliferative disease [92" ]. She responded to withdrawal of mycophenolate mofetil, intravenous methotrexate, rituximab, and... 

Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener s granulomatosis. Arthritis Rheum 2004 51 278-283. 

Nowack R Gobel U, Klooker P, et al. Mycophenolate mofetil for maintenance therapy of Wegener s granulomatosis and microscopic polyangiitis a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999 10(9) 1965-1971. 

Nowack R, Birck R, van der Woude FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997 349(9054) 774. 

Whyte RI, Rossi SJ, Mulligan MS, Florn R, Baker L, Gupta S, Martinez FJ, Lynch JP 3rd (1997) Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation. Ann Thorac Surg 64 945-948... 

---